




Vol. 31 - 1-2 - 2009  
Central European Journal of

# IMMUNOLOGY



FOUNDED SOCIETY FOR IMMUNOLOGY AND PATHOLOGY (CESIP)  
CENTRAL EUROPEAN SOCIETY FOR IMMUNOLOGY

ISSN 1084-0899

www.cesip-journal.com

Published online in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/cei

# Interaction and cellular uptake of surface-modified carbon dot nanoparticles by J774.1 macrophages

LESTER THOO<sup>1</sup>, MOCHAMAD Z. FAHMP<sup>2</sup>, IHSAN N. ZULKIPLI<sup>1</sup>, NATASHA KEASBERRY<sup>3</sup>, ADI IDRIS<sup>1</sup>

<sup>1</sup>PAPRSB Institute of Health Science, Universiti Brunei Darussalam, Brunei Darussalam

<sup>2</sup>Department of Chemistry, Universitas Airlangga, Indonesia

<sup>3</sup>Faculty of Science, Universiti Brunei Darussalam, Brunei Darussalam

## Abstract

Carbon dot (Cdot) nanoparticles are an emerging class of carbon nanomaterials with a promising potential for drug delivery and bio imaging applications. Although the interaction between Cdots and non-immune cell types has been well studied, Cdot interactions with macrophages have not been investigated. Exposure of Cdot nanoparticles to J774.1 cells, a murine macrophage cell line, resulted in minimal toxicity, where notable toxicity was only seen with Cdot concentrations higher than 0.5 mg/ml. Flow cytometric analysis revealed that Cdots prepared from citric acid were internalized at significantly higher levels by macrophages compared with those prepared from bamboo leaves. Interestingly, macrophages preferentially took up phenylboronic acid (PB)-modified nanoparticles. By fluorescence microscopy, strong blue light-specific punctate Cdot fluorescence resembling Cdot structures in the cytosolic space was mostly observed in J774.1 macrophages exposed to PB-modified nanoparticles and not unmodified Cdot nanoparticles. PB binds to sialic acid residues that are overexpressed on diseased cell surfaces. Our findings demonstrate that PB-conjugated Cdots can be taken up by macrophages with low toxicity and high efficiency. These modified Cdots can be used to deliver drugs to suppress or eliminate aberrant immune cells such as macrophages associated with tumors such as tumor-associated macrophages.

**Key words:** carbon dots, macrophage, nanoparticles, phenylboronic acid, J774.1 cells.

(*Centr Eur Immunol* 2017; 42 (2): 324-330)

## Introduction

Cdot nanoparticles are an emerging group of fluorescent nanomaterials or quantum dots with excellent photoluminescence and biocompatibility [1]. These water-soluble nanoparticles exert minimal cellular toxicity because they do not contain toxic heavy metals unlike their other fluorescent counterparts, quantum dots and some organic dyes [2]. Cdots have the ability to emit specific wavelengths of light, which resembles the optical properties of conventional quantum dots [3]. Furthermore, Cdots are relatively easy and inexpensive to synthesize and subject to surface modifications. Generally, Cdots consist of carbon, hydrogen and oxygen, and their carbon configuration with a quasi-spherical form has a promising potential in a number of applications such as probes for bio imaging and in optoelectronic and biosensor technologies [4].

Cdots have also been tested for the delivery of therapeutic agents. Recent studies have shown that Cdots can be used to deliver nucleic acids into target cells for gene therapy, both *in vivo* and *in vitro* [5-9]. Furthermore, Cdots have been applied to intracellular drug delivery [10-12]. However, *in vitro* studies to date have only tested the effects of Cdot exposure on non-immune cell types. It is possible that Cdot toxicity and cellular uptake may vary in other cell types, which is important because different mechanisms of nanoparticle uptake may dictate the mode that the loaded "cargo" is processed by the cells. In this study, we examined how Cdots interact with macrophages, an immune cell type that has an exceptional ability to take up extracellular particulate matter such as nanoparticles. Subsequently, we explored the interactions between various Cdot preparations with different surface modifications and J774.1 cells, a murine macrophage cell line, by assessing Cdot cytotoxicity and uptake efficiency. There is

Correspondence: Adi Idris, PAPRSB Institute of Health Science, Universiti Brunei Darussalam Jalan Tungku Link Gadong, BE1410 Bandar Seri Begawan, Brunei Darussalam, e-mail: [yusri.idris@ubd.edu.bn](mailto:yusri.idris@ubd.edu.bn)

Submitted: 23.03.2016; Accepted: 13.06.2016

growing interest in taking advantage of sialic acid (SA), which is expressed highly on cell surfaces in disease states (e.g. oncogenic transformation) [13], as a “tag” for diseased cells. It is known that phenylboronic acid (PB) reacts strongly with SA residues with high affinity and specificity [14]. This property makes PB an ideal ligand that allows highly specific and efficient labeling of SA residues on cells. We therefore functionalized the surface of the Cdots with PB groups in our study to determine whether this modification enhances cellular uptake of Cdots.

In this study, we found that Cdots exerted low toxicity in J774.1 macrophages, even at high amounts. Flow cytometry and fluorescence microscopy revealed that J774.1 macrophages internalized citric acid (CA)-derived Cdots more efficiently than Cdots prepared from an alternative source of carbon, cellulose from bamboo leaf (BA). Specifically, J774.1 macrophages showed high efficiency for taking up PB-modified CA-derived Cdots.

## Material and methods

### Chemicals

4',6-Diamidine-2'-phenylindole dihydrochloride (DAPI) was obtained from Invitrogen (Grand Island, NY). Alexa Fluor® 647 Phalloidin (Cat# A22287) was obtained from Molecular Probes (Waltham, MA). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) and carboxyl phenylboronic acid (CBBA) were obtained from Sigma-Aldrich (St. Louis, MO).

### Preparation of Cdots

Cdots were prepared by pyrolyzing either CA or BA. For nanoparticles prepared from CA, 200 mg CA was calcined at 240°C for 30 min before cooling to room temperature. This process turned CA into an orange color, owing to carbonization and the generation of graphitic nanostructures. For nanoparticles prepared from BA, 200 mg of sliced bamboo leaves were refluxed with 10 ml of 2% NaOH for 5 h. After washing with water, cellulose was mixed with 10 ml of 5% NaOCl using a magnetic stirrer for 2 h and then centrifuged at 700 g for 5 min. To pyrolyze the cellulose, 200 mg cellulose was calcined at 540°C for 30 min before cooling to room temperature. After calcination of CA- and BA-prepared nanoparticles, 0.5 M NaOH was added until the pH became neutral. To narrow the size distribution of the nanoparticles and remove small molecules, nanoparticles were passed through centrifugal filter units with a 1 kDa molecular weight cut-off.

### Conjugating CBBA to Cdots

10 ml of CBBA solution was prepared by adding 2.4 mg 4-dimethylaminopyridine to a 0.3 mg/ml CBBA solution before adding 3.1 mg of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide. After mixing for 30 min, 5 ml of CA-

or BA-prepared nanoparticles was added to the mixture, followed by stirring for 24 h. The mixture then underwent dialysis for 24 h.

### J774.1 macrophage culture

J774.1 cells were obtained from the American Type Tissue Culture Collection (Manassas, VA). Cells were cultured in complete medium consisting of RPMI 1640 medium supplemented with 10% fetal calf serum, 2 mM L-glutamine, 20 U/ml penicillin, and 20 µg/ml streptomycin (all purchased from Gibco, Carlsbad, CA) and grown on bacteriological plastic (Sterilin, Newport, United Kingdom).

### Exposure of Cdots to J774.1 macrophages

Cells ( $4 \times 10^5$  cells) were seeded in 12-well or 96-well plates (Corning, Tewksbury, MA), incubated overnight, and then treated with or without various concentrations (5 mg/ml to 5 ng/ml) of different Cdot preparations previously dissolved in sterile water, for 24 h before performing MTT assays. Sterile water was used as the vehicle control. For microscopic analysis of internalized Cdots, cells ( $4 \times 10^5$ /well) were seeded on autoclaved glass coverslips in 12-well plates (Corning, Tewksbury, MA), incubated overnight, and then treated with nanoparticles.

### Assessment of Cdot cytotoxicity in J774.1 macrophages

An MTT assay was performed to measure cell viability. After 24 h, cell medium was replaced with a solution of 1 mg/ml MTT in phosphate-buffered saline (PBS), followed by incubation for 1 h at 37°C. After removing the MTT solution, 200 µl of a 50% isopropanol/10% SDS solution was added to each well, followed by incubation in the dark overnight. The absorbance of the wells was measured spectrophotometrically at 570 nm on a BioTek ELx808 ELISA plate reader (BioTek, Winooski, VT).

### Measurement of cellule uptake of Cdots by flow cytometry

At 24 h post-treatment with Cdots, the medium was discarded and the cells were rinsed with PBS. Cell monolayers were fixed *in situ* for 5 min with 4% (w/v) paraformaldehyde (PFA) in PBS and then rinsed with PBS. PBS (250 µl) was added to the cells before carefully scraping the cells off the plate. The cells were transferred into clean tubes for intracellular fluorescence analysis on a BD Accuri® C6 Flow Cytometer (BD Bioscience, San Jose, CA).

### Immunofluorescence staining and microscopic visualization of internalized Cdots

At 24 h post-treatment with Cdots, the medium was discarded and the cells were rinsed with PBS. Cell monolayers on glass coverslips were then fixed *in situ* for 5 min

**Table 1.** Cdots used in this study


Cdots	Abbreviation
Cdots prepared from citric acid	CDA
Boronic acid-conjugated Cdots prepared from citric acid	CDA/CBBA
Cdots prepared from bamboo leaf	CDB
Boronic acid-conjugated Cdots prepared from bamboo leaf	CDB/CBBA

with 4% (w/v) PFA and 0.1% Triton X-100 in PBS. After rinsing with PBS, the cells were incubated with Alexa Fluor® 647 Phalloidin at a dilution of 1/40 in PBS for 20 min at room temperature in the dark and then rinsed three times with PBS. The cells were washed once in PBS and then stained with 10 ng/mL DAPI in PBS for 10 min in the dark. After washing in PBS, the cells were mounted with DakoCytomation fluorescence mounting medium (Dako, Glostrup, Denmark) under a coverslip. The cells were then analyzed using an epi-fluorescence microscope (Nikon inverted microscope Eclipse 90L) at 100× magnification.

## Results

### Physicochemical properties of Cdots

Spectroscopic characterization and microscopy were carried out to determine the physicochemical properties of the prepared Cdots (Table 1). The PL spectra for both CDA and CDB showed that the particles exhibited fluorescence emission at 480 nm ( $\lambda_{ex} = 420$  nm) (Fig. 1A), similar to Cdots reported by Zakki *et al.* [12]. Although some larger particles were observed (above 15 nm), AFM analysis revealed the average size distribution for the majority of CDA and CDB nanoparticles to be 3 nm and 5 nm, respectively (Fig. 1B). Raman spectroscopy confirmed that CDA and CDB nanoparticles had similar Raman spectral patterns (Fig. 1C). When compared to the Raman spectra of CA or BA alone, the Raman absorption profiles of CDA and CDB demonstrated similar characteristics. Both had peaks at 1332 and 1582 nm (D and G bands respectively) which correlate to  $sp^2$ - and  $sp^3$ -hybridized carbon atoms, respectively. These findings confirm that the prepared Cdots had the expected characteristics, which were similarly shared by CDA and CDB nanoparticles.



**Fig. 1.** Physicochemical properties of Cdots used in this study. A) UV–Vis absorption spectra (solid line) and PL emission spectra (dotted line) of prepared CDA (red) and CDB (blue). The sample was measured at  $\lambda_{ex} = 420$  nm. B) AFM characterization of CDA and CDB on the cross-sectional side of the samples. C) Raman spectra of CA (black), BA (green), CDA (red) and CDB (blue) samples

## Cdots have minimal toxicity in J774.1 macrophages

The toxicity of Cdots *in vitro* has only been tested in non-immune cell lines such as HeLa [12, 15], MCF-7 [5], MDA-MB231 [5], Vero [15], and L929 [16]. Therefore, we tested the toxicity of Cdots in J774.1 macrophages after 24 h of exposure to various Cdot preparations using the MTT assay, a colorimetric assay that measures the metabolic activity of cells. Compared with the vehicle control (water), cells treated with increasing doses of Cdots maintained high viability (> 90% viability) (Fig. 2). Notable toxicity was only seen at higher Cdot concentrations (0.5–5 mg/ml). With the exception of CDB, treatment with other Cdot preparations only resulted in less than 50% percent loss of cell viability at the highest dose (5 mg/ml) compared with water treatment alone. Overall, we found that Cdots exerted minimal toxicity in J774.1 macrophages and that the optimal dose for subsequent Cdot uptake experiments was 0.05 mg/ml.

## CDA/CBBA is internalized most efficiently by J774.1 macrophages

Upon exposure to particulate matter such as nanoparticles, macrophages are an important cell type for elicitation of innate immune responses and the destruction and/or clearance of particles from tissues. Prior to these events, macrophages internalize the particles. To assess the efficiency of Cdot uptake by J774.1 macrophages, various Cdot preparations were exposed to adherent cells for 24 h to allow the Cdots to be internalized before analyzing the cells by flow cytometry and fluorescence microscopy. The excitation-dependent fluorescence of Cdots (blue light;  $\lambda = 488$  nm) allowed visualization of Cdots intracellularly. Compared with the control, J774.1 macrophages internalized significantly more CA-derived Cdots (CDA and CDA/CBBA) than BA-derived Cdots (CDB and CDB/CBBA) ( $p < 0.05$ ) (Fig. 3A and B). Although not statistically significant, J774.1 cells exposed to the PB-modified form of CDA, CDA/CBBA, had a higher mean fluorescence intensity compared with cells exposed to CDA (Fig. 3B). Nonetheless, the percentage uptake of CDA/CBBA was markedly higher than that of CDA (Fig. 3A). These findings suggest that J774.1 macrophages internalize CDA nanoparticles more efficiently than CDB nanoparticles, and that surface PB-modification appears to enhance the uptake of CDA nanoparticles.


## Internalized CDA/CBBA appear as “punctate dots” in the cytosol

Flow cytometric analysis showed that more PB-modified CDA nanoparticles were taken up by cells compared with non-PB-modified CDA nanoparticles (Fig. 3A). To confirm this result, we performed fluorescence microscop-


ic analysis of the internalized Cdots at 24 h post-exposure. Strong blue light-specific punctate Cdot fluorescence resembling Cdot structures in the cytosolic space was mostly observed in J774.1 macrophages exposed to CDA/CBBA nanoparticles and not unmodified CDA or other Cdot nanoparticles (Fig. 4). This finding demonstrates that J774.1 macrophages preferentially take up CDA/CBBA nanoparticles compared with the other tested Cdots.

## Discussion

Initially, we performed physicochemical studies to ensure that the prepared Cdots had the correct characteristics. The UV spectra of Cdots is mostly attributed by  $\pi-\pi^*$  transitions in the aromatic sp<sup>2</sup> carbon atom domains [12, 17]. The emission results from the formation of carbon crystals on the graphene-like structure and the expansion of the orbital state due to the sp<sup>2</sup> and sp<sup>3</sup> carbon structures, which drive on discrete quantized orbital energy levels [18]. Although the UV spectral patterns for CDA and CDB were similar, AFM analysis revealed that the nanoparticle sizes between CDA and CDB slightly differ (e.g. 3 nm for CDA and 5 nm for CDB). Moreover, the pyrolysis process of citric acid yields CDA particles which are relatively smaller than CDB. It is possible that during the pyrolysis process of CA, CA molecules were re-arranged to form larger structures in CDA and leading to its smaller size distribution than CDB. Raman spectroscopy revealed sp<sup>2</sup> (D band) and sp<sup>3</sup> (G band) carbon structures



**Fig. 2.** Minimal toxicity of Cdots in J774.1 cells. J774.1 cells were incubated with various concentrations of different Cdot preparations for 24 h before measuring cell viability by MTT assays. Percentage cell viability was determined by comparing the effect of Cdots with the vehicle control (water). Data represent the mean  $\pm$  SEM of four independent experiments




**Fig. 3.** J774.1 cells internalize CDA/CBBA nanoparticles more efficiently compared with other Cdote nanoparticles. J774.1 cells were incubated with 0.05 mg/ml of various Cdote preparations or water (-) for 24 h before A) measuring the percentage of Cdote uptake (488 nm) by flow cytometry. Results are representative of four independent experiments. B) Examples of (A) are shown with graphs showing the mean fluorescence intensity (MFI)  $\pm$  SEM from four independent experiments; \* $p < 0.05$ , Student's  $t$  test

which suggests the presence of graphene-like structures. The presence of these bands in Cdotes further supports the  $sp^2$  graphitic-defect sites in  $sp^3$  amorphous carbon, which is responsible for its photo luminescent properties.

In this study, we produced water-soluble Cdote nanoparticles conjugated with PB groups on their surface. As mentioned previously, PB has a high affinity for glycoproteins such as SA that is overexpressed on a wide variety of pathological cells [13]. Because PB groups can be used to target SA ligands on diseased cells, PB-conjugated Cdotes could potentially be used as molecular imaging probes and drug delivery agents targeting diseased cells such as tumor cells. Our observation that Cdotes exert minimal toxicity in J774.1 cells corroborates previous findings in other cell types [5, 12, 15]. To our knowledge, this is the first study to investigate the interaction between Cdote nanoparticles and macrophages. A previous study by Qin *et al.* [19] showed that exposure of human macrophages to graphene quantum dots, a carbon material family member, results in apoptotic cell death and production of reactive oxygen species. Our findings suggest that Cdotes could be

used as a non-toxic alternative to graphene quantum dots for a number of applications.

We found that J774.1 macrophages took up significantly more CA-prepared Cdotes than BA-prepared Cdotes. This result suggests that the source of carbon for preparing Cdote dictates the uptake efficiency by macrophage, possibly due to the differences in the surface chemistry of the Cdotes. Cellular uptake is generally influenced by several properties including size, shape and surface charge of nanoparticles [20]. It is possible the surface charge on the Cdotes may vary depending on the carbon source. Future work is required to assess the surface charge of Cdotes by dynamic light scattering (DLS) analysis. Nanoparticles are mainly internalized into phagocytic cells such as macrophages via fluid phase endocytosis, receptor-mediated endocytosis, and phagocytosis [21]. The uptake mechanism of Cdotes by macrophages is not yet understood. Future studies to elucidate this mechanism are crucial to understand the detailed dynamics of the Cdote internalization process. It is interesting to note that PB-coated CDA was more efficiently taken up by macrophages. The murine J774.1 macrophage cell line was originally derived from a tumor (reticulum cell



**Fig. 4.** Internalized CDA/CBB nanoparticles are localized in the cytosolic space. J774.1 cells were incubated with 0.05 mg/ml of various Cdot preparations or water (-) for 24 h before fixing the cells for immunofluorescence staining and microscopic analysis of internalized Cdots. Cell nuclei (blue) and filamentous actin (red) were stained with DAPI and Phalloidin-647, respectively, before observing under a fluorescence microscope at  $\times 100$  magnification. Cdot fluorescence was detected at a wavelength of 488 nm (green). Data are representative of four independent experiments

carcinoma)-bearing mouse [22]. Considering its cancerous (i.e. diseased) origin, it is possible that SA groups are highly expressed on the cell surface of J774.1 macrophages, and therefore preferentially internalize PB-modified Cdots. However, we have not demonstrated this experimentally. To confirm this, future work will assess the cellular uptake of Cdots using macrophages treated with sialidase, which is used to cleave sialic acid residues from the cells, or using non-treated macrophages cultured in the presence of free PBA, as performed previously on murine melanoma cells [23]. Furthermore, Cdot uptake experiments using human and murine primary macrophages will be necessary to definitively elucidate macrophage interactions with Cdots in a non-diseased state.

Cell-specific imaging to target specific cell populations for diagnosis (e.g. tumor cells) and eventual cell-directed therapy is critical to attain high therapeutic success. In cancer, abnormal sialylation is a characteristic associated with malignant properties including invasiveness and metastatic potential [24]. Therefore, alterations associated

with sialylation facilitate early diagnosis, prognosis, and post-treatment monitoring of various cancers. There is increasing interest to develop PB-functionalized nanocarriers for specific targeting of SA groups to improve drug delivery in cancer therapy [25]. Considering that Cdots have a promising potential for bio imaging [4], Cdots bearing PB surface modifications could serve as a good nanocarrier candidate for drug delivery into SA-expressing cells (i.e. diseased cells). Future study will focus on elucidating the mechanism of Cdot uptake by phagocytic cells such as macrophages. Furthermore, the exact mechanism of *in vivo* bio distribution, cellular uptake, and long-term toxicological effects of Cdots remain to be investigated.

This study represents an advance in the field of fluorescent nanomaterial research. Our findings demonstrate that PB-conjugated Cdots can be taken up into macrophages *in vitro* with low toxicity and high efficiency for a number of potential biological applications such as intracellular tracking of internalized Cdot-coupled antigens and drug/vaccine delivery for cellular immunotherapy. Importantly,

macrophage-associated delivery of drugs can be used to suppress or eliminate macrophages associated with tumors (i.e. tumor-associated macrophages) [26].

---

*This work was supported by the Southeast and South Asia and Taiwan Universities (SATU) Joint Research Scheme.*

*The authors declare no conflict of interest.*

## References

1. Wang J, Liu G, Cham-Fai Leung K, Loffroy R, et al. (2015): Opportunities and Challenges of Fluorescent Carbon Dots in Translational Optical Imaging. *Current pharmaceutical design* 21: 5401-5416.
2. Resch-Genger U, Grabolle M, Cavaliere-Jaricot S, et al. (2008): Quantum dots versus organic dyes as fluorescent labels. *Nat Met* 5: 763-775.
3. Fu M, Ehrat F, Wang Y, et al. (2015): Carbon dots: a unique fluorescent cocktail of polycyclic aromatic hydrocarbons. *Nano Lett* 15: 6030-6035.
4. Shi H, Wei J, Qiang L, et al. (2014): Fluorescent carbon dots for bioimaging and biosensing applications. *J Biomed Nanotech* 10: 2677-2699.
5. Misra SK, Ohoka A, Kolmodin NJ, et al. (2015): Next generation carbon nanoparticles for efficient gene therapy. *Mol Pharm* 12: 375-385.
6. Pierrat P, Wang R, Kereselidze D, et al. (2015): Efficient in vitro and in vivo pulmonary delivery of nucleic acid by carbon dot-based nanocarriers. *Biomaterials* 51: 290-302.
7. Wang L, Wang X, Bhirde A, et al. (2014): Carbon-dot-based two-photon visible nanocarriers for safe and highly efficient delivery of siRNA and DNA. *Adv Healthc Mater* 3:1203-1209.
8. Liu C, Zhang P, Zhai X, et al. (2012): Nano-carrier for gene delivery and bioimaging based on carbon dots with PEI-passivation enhanced fluorescence. *Biomaterials* 33: 3604-3613.
9. Das S, Debnath N, Cui Y, et al. (2015): Chitosan, Carbon Quantum Dot, and Silica Nanoparticle Mediated dsRNA Delivery for Gene Silencing in *Aedes aegypti*: A Comparative Analysis. *ACS Appl Mater Interfaces* 7: 19530-19535.
10. Zhou L, Li Z, Liu Z, Ren J, et al. (2013): Luminescent carbon dot-gated nanovehicles for pH-triggered intracellular controlled release and imaging. *Langmuir* 29: 6396-6403.
11. Patra S, Roy E, Madhuri R, et al. (2016): The next generation cell-penetrating peptide and carbon dot conjugated nano-liposome for transdermal delivery of curcumin. *Biomater Sci* 4: 418-429.
12. Fahmi MZ, Chen JK, Huang CC, et al. (2015): Phenylboronic acid-modified magnetic nanoparticles as a platform for carbon dot conjugation and doxorubicin delivery. *J Materials Chemistry B* 3 (27): 5532-5543.
13. Varki A (2008): Sialic acids in human health and disease. *Trends Molecular Med* 14: 351-360.
14. Liu A, Peng S, Soo JC, et al. (2010): Quantum dots with phenylboronic acid tags for specific labeling of sialic acids on living cells. *Anal Chem* 83: 1124-1130.
15. Dekaliuk M, Pyrshev K, Demchenko A (2015): Visualization and detection of live and apoptotic cells with fluorescent carbon nanoparticles. *J Nanobiotechnology* 13: 86.
16. Du F, Ming Y, Zeng F, et al. (2013): A low cytotoxic and ratiometric fluorescent nanosensor based on carbon-dots for intracellular pH sensing and mapping. *Nanotechnology* 24: 365101.
17. Shi QQ, Li YH, Xu Y, et al. (2014): High-yield and high-solubility nitrogen-doped carbon dots: formation, fluorescence mechanism and imaging application. *RSC Advances* 4: 1563-1566.
18. Purbia R, Paria S (2016): A simple turn on fluorescent sensor for the selective detection of thiamine using coconut water derived luminescent carbon dots. *Biosens Bioelectron* 79: 467-475.
19. Qin Y, Zhou ZW, Pan ST, et al. (2015): Graphene quantum dots induce apoptosis, autophagy, and inflammatory response via p38 mitogen-activated protein kinase and nuclear factor- $\kappa$ B mediated signaling pathways in activated THP-1 macrophages. *Toxicology* 327: 62-76.
20. Fröhlich E (2012): The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. *Int J Nanomedicine* 7: 5577-5591.
21. Roy R, Kumar S, Tripathi A, et al. (2014): Interactive threats of nanoparticles to the biological system. *Immunol Lett* 158: 79-87.
22. Ralph P, Nakoinz I (1975): Phagocytosis and cytolysis by a macrophage tumour and its cloned cell line. *Nature* 257: 393-394.
23. Deshayes S, Cabral H, Ishii T, et al. (2013): Phenylboronic acid-installed polymeric micelles for targeting sialylated epitopes in solid tumors. *J Am Chem Soc* 135: 15501-15507.
24. Vajaria BN, Patel KR, Begum R, et al. (2015): Sialylation: an Avenue to Target Cancer Cells. *Pathol Oncol Res* 22: 443-447.
25. Wang J, Wu W, Jiang X (2015): Nanoscaled boron-containing delivery systems and therapeutic agents for cancer treatment. *Nanomedicine* 10: 1149-1163.
26. Vinogradov S, Warren G, Wei X (2014): Macrophages associated with tumors as potential targets and therapeutic intermediates. *Nanomedicine* 9: 695-707.



WEBINARIUM

**SZCZEPIENIA ZALECANE U DZIECI  
- UPDATE W CIENIU COVID-19**

25 MAJA 2021 / GODZ. 18:30



Central European Journal of

**IMMUNOLOGY**



# Central European Journal of Immunology

eISSN: 1644-4124

ISSN: 1426-3912

[Current issue](#)

[Archive](#)

[Manuscripts accepted](#)

[About the journal](#)

[Editorial board](#)

[Abstracting and indexing](#)

[Subscription](#)

[Contact](#)

[Instructions for authors](#)

[Ethical standards and procedures](#)

[Editorial System](#)

[Submit your Manuscript](#)

Central-European Journal of  
Immunology

Q3

Immunology and  
Allergy

best quartile

SJR 2020

0.56



powered by scimagojr.com

Ta strona używa pliki cookies, w celu polepszenia użyteczności i funkcjonalności oraz w celach statystycznych. Dowiedz się więcej w Polityce prywatności.

Korzystając ze strony wyrażasz zgodę na używanie plików cookies, zgodnie z aktualnymi ustawieniami przeglądarki.

Akceptuję wykorzystanie plików cookies

## Search

# XVII Congress of the Polish Society of Experimental and Clinical Immunology

May 27-29th, 2021, Medical University of  
Białystok, Poland

**editorial board**

**Tadej Avcin**, Department of Allergology, Rheumatology and Clinical Immunology, University Children's Hospital Ljubljana, Slovenia

**Jarosław Baran**, Jagiellonian University, Department of Immunology, Krakow, Poland

**Ewa Bernatowska**, Clinic of Gastroenterology, Hepatology and Immunology Institute "Memorial - Children's Health Center", Warsaw, Poland

**Leszek K. Borysiewicz**, Department of Medicine, University of Wales College of Medicine, Cardiff, Wales, United

Ta strona używa pliki cookies, w celu polepszenia użyteczności i funkcjonalności oraz w celach statystycznych. Dowiedz się więcej w Polityce prywatności.

Korzystając ze strony wyrażasz zgodę na używanie plików cookies, zgodnie z aktualnymi ustawieniami przeglądarki.

---

**Victor P. Chernyshov**, Laboratory of Immunology, Institute of Pediatrics, Obstetrics and Gynecology, Kiev, Ukraine

**Joanna Chorostowska-Wynimko**, Laboratory of Molecular Diagnostics, National Institute of Tuberculosis and Lung Diseases, Warsaw, Poland

**Peter Ciznar**, Pediatric Clinic of L. Derer's Hospital, Bratislava, Slovakia

**Zbigniew Darżynkiewicz**, The Brander Cancer Research Institute, New York Medical College, Valhalla, New York, USA

**Wiesław Deptuła**, Chair of Microbiology and Immunology, Faculty of Natural Sciences, University of Szczecin, Poland

**Melinda Erdos**, Department of Infectology and Pediatric Immunology, University of Debrecen, Debrecen, Hungary

**John L. Fahey**, Department of Microbiology and Immunology, UCLA School of Medicine, Los Angeles, USA

**Marc Feldmann**, Medicine, DIIID, Rheumatology, King's College London, Strand, London, UK

**Hans D. Flad**, Research Center Borstel, Department of Immunology and Cell Biology, Borstel, Germany

**Zbigniew Gacjong**, Department of Internal Diseases, Hypertension and Vascular Disease, the Medical University of Warsaw, Warsaw, Poland

**Alenka Gagro**, Institute of Immunology, University Children's Hospital, Zagreb, Croatia

**Andrzej Górski**, Department of Clinical Immunology Transplantation Institute, Medical University of Warsaw, Warsaw, Poland; Phage Therapy Unit, Hirszfild Institute of Immunology & Experimental Therapy, Bacteriophage Laboratory, Hirszfild Institute of Immunology & Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland

**Marek Jakóbiński**, Department of Immunology Center of Biostructure Research, The Medical University of Warsaw, Warsaw, Poland

**Wiesław W. Jędrzejczak**, Department of Hematology, Oncology and Internal Diseases, Medical University of Warsaw, Warsaw, Poland.

**Michel Kazatchkine**, UN Special Envoy for HIV in eastern Europe and central Asia, Geneva, Switzerland; Institute of Biology and Immunology of Reproduction, Sofia, Bulgaria; University of the Mediterranean, Marseilles, France

**Rakhim Khaitov**, National Research Center "Institute of Immunology", Ministry of Public Health, Moscow, Russia

**Paweł Kisielow**, Department of Immunology, Institute of Immunology & Experimental Therapy, Wrocław, Poland

**Vladimir Kotnik**, Institute of Microbiology, Medical Faculty, University of Ljubljana, Slovenia

**Marek L. Kowalski**, Department of Immunology, Rheumatology and Allergy, Medical University of Lodz, Lodz, Poland

**Maciej Kurpisz**, Institute of Human Genetics, Polish Academy of Sciences, Poznan, Poland

**Andrzej Lange**, Lower Silesian Center for Cellular Transplantation with National Bone Marrow Donor Registry, Wrocław, Poland; Laboratory and Department of Clinical Immunology, L. Hirszfild, Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland; Center for Vaccinology, Ghent University and Hospital, Ghent, Belgium

**Foo Yew Liew**, Division of Immunology, Infection and Inflammation, Glasgow Biomedical Research Centre, University of Glasgow, United Kingdom

---

**Thi-Hien Tran**, Department of Clinical Immunology and Allergy, Maastricht University, Breda, The Czech Republic

Ta strona używa pliki cookies, w celu polepszenia użyteczności i funkcjonalności oraz w celach statystycznych. Dowiedz się więcej w Polityce prywatności.

Korzystając ze strony wyrażasz zgodę na używanie plików cookies, zgodnie z aktualnymi ustawieniami przeglądarki.

Akceptuję wykorzystanie plików cookies



**Włodzimierz Maśliński**, Department of Pathophysiology and Immunology, Institute of Rheumatology, Warsaw, Poland

**Waldemar L. Olszewski**, Department of Surgical Research and Transplantology, Medical Research Center, Polish Academy of Sciences, Warsaw, Poland

**Barbara Płytycz**, Department of Evolutionary Immunology, Institute of Zoology, Jagiellonian University, Krakow, Poland

**Ludmila Prokesova**, Institute of Immunology and Microbiology, First Faculty of Medicine, Charles University, Prague, Czech Republic

**Czesław Radzikowski**, Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland

**Jacek Roliński**, Department of Clinical Immunology, Medical University, Lublin, Poland

**Barry T. Rouse**, Department of Genome Science and Technology, University of Tennessee, Knoxville, Tennessee, USA; Biomedical and Diagnostic Sciences, College of Veterinary Medicine, The University of Tennessee, Knoxville, USA

**Sylwia Słotwińska**, Department of Conservative Dentistry, Medical University of Warsaw, Warsaw, Poland

**Robert Słotwiński**, Department of Surgical Research and Transplantology Polish Academy of Sciences Medical Research Center, Warsaw, Poland; Department of Immunology and Nutrition Medical University of Warsaw, Warsaw, Poland

**Monika Szturmowicz**, Department of Chest Medicine, Institute of Tuberculosis and Lung Diseases, Warsaw, Poland

**Janusz Ślusarczyk**, Departments of Immunopathology and Hepatology, Institute of Infectious and Parasitic Diseases, Warsaw, Poland

**Vincas Tamosiunas**, Vilnius University, Vilnius, Lithuania

**Leonid Titov**, Belarusian Research Institute for Epidemiology and Microbiology, Minsk, Belarus

**Raivo Uibo**, Institute of General and Molecular Pathology University of Tartu, Tartu Estonia

**Janina Wyczółkowska**, Department of Biogenic Amines, Molecular Research Center of the Polish Academy of Sciences, Łódź

**Krzysztof Zeman**, Department of Paediatrics and Clinical Immunology, Medical University, Lodz, Poland

**Maria Zembala**, Department of Plant Physiology, Polish Academy of Sciences, Krakow, Poland

## Termedia

About us   Copyright notice  
Contact   Privacy policy  
Advertising policy  
Contact us

## Quick links

Journals  
Books  
eBooks  
Events

Ta strona używa pliki cookies, w celu polepszenia użyteczności i funkcjonalności oraz w celach statystycznych. Dowiedz się więcej w Polityce prywatności.

Korzystając ze strony wyrażasz zgodę na używanie plików cookies, zgodnie z aktualnymi ustawieniami przeglądarki.

Akceptuję wykorzystanie plików cookies

# Source details

## Central-European Journal of Immunology

Formerly known as: Polish Journal of Immunology

Open Access ⓘ

Scopus coverage years: from 1996 to 2022

Publisher: Termedia Publishing House Ltd.

ISSN: 1426-3912 E-ISSN: 1644-4124

Subject area: Medicine: Immunology and Allergy Immunology and Microbiology: Immunology

Source type: Journal

CiteScore 2021 ⓘ  
**2.9**

SJR 2021 ⓘ  
**0.435**

SNIP 2021 ⓘ  
**0.696**

[View all documents >](#) [Set document alert](#) [Save to source list](#) [Source Homepage](#)

[CiteScore](#) [CiteScore rank & trend](#) [Scopus content coverage](#)

### i Improved CiteScore methodology

CiteScore 2021 counts the citations received in 2018-2021 to articles, reviews, conference papers, book chapters and data papers published in 2018-2021, and divides this by the number of publications published in 2018-2021. [Learn more >](#)

CiteScore 2021 ⌵

$$2.9 = \frac{758 \text{ Citations 2018 - 2021}}{259 \text{ Documents 2018 - 2021}}$$

Calculated on 05 May, 2022

CiteScoreTracker 2022 ⓘ

$$2.7 = \frac{632 \text{ Citations to date}}{233 \text{ Documents to date}}$$

Last updated on 05 April, 2023 • Updated monthly

## CiteScore rank 2021 ⓘ

Category	Rank	Percentile
Medicine		
Immunology and Allergy	#142/200	29th
Immunology and Microbiology		
Immunology	#164/213	23rd

[View CiteScore methodology >](#) [CiteScore FAQ >](#) [Add CiteScore to your site &](#)

---

## About Scopus

[What is Scopus](#)

[Content coverage](#)

[Scopus blog](#)

[Scopus API](#)

[Privacy matters](#)

## Language

[日本語版を表示する](#)

[查看简体中文版本](#)

[查看繁體中文版本](#)

[Просмотр версии на русском языке](#)

## Customer Service

[Help](#)

[Tutorials](#)

[Contact us](#)

---

## ELSEVIER

[Terms and conditions](#) ↗ [Privacy policy](#) ↗

Copyright © Elsevier B.V. ↗. All rights reserved. Scopus® is a registered trademark of Elsevier B.V.

We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies ↗.



## Central-European Journal of Immunology

### COUNTRY

Poland



Universities and research institutions in Poland

### SUBJECT AREA AND CATEGORY

Immunology and Microbiology  
Immunology

Medicine  
Immunology and Allergy

### PUBLISHER

Termedia Publishing House Ltd.

### H-INDEX

22

### PUBLICATION TYPE

Journals

### ISSN

14263912,  
16444124

### COVERAGE

1996-2020

### INFORMATION

[Homepage](#)

[How to publish in this journal](#)

[ceji11@uckwum.pl](mailto:ceji11@uckwum.pl)

vivo

Central European Journal of Immunology is a English-language quarterly aimed mainly at immunologists.


Join the conversation about this journal

Quartiles


FIND SIMILAR JOURNALS ?

<p>1 <b>Journal of Immunology Research</b> EGY</p> <p><b>72%</b> similarity</p>	<p>2 <b>Immunologic Research</b> USA</p> <p><b>70%</b> similarity</p>	<p>3 <b>Mediators of Inflammation</b> USA</p> <p><b>67%</b> similarity</p>	<p>4 <b>Cytokine</b> USA</p> <p><b>6</b> s</p>
---	---	--	--


SJR







Total Cites Self-Cites



Citations per document







**Central-European Journal of Immunology**

Q3 Immunology and Allergy  
best quartile

SJR 2020  
0.56

powered by scimagojr.com

← Show this widget in your own website

Just copy the code below and paste within your html code:

```
<a href="https://www.scimagojr.com" style="border: 1px solid black; padding: 2px 5px; display: inline-block;">https://www.scimagojr.com
```

Metrics based on Scopus® data as of April 2021

**Leave a comment**

Name

Email

(will not be published)



99+

## [MaC16-03-062] Manuscript Submission Confirmation.



**Molecules and Cells** <home@ksmcb.or.kr>

to me

# Molecules and Cells

[Aims and Scope](#)

[Instructions to Authors](#)

[Archives](#)

Manuscript ID: MaC16-03-062

Manuscript Title: Interaction and cellular uptake of surface-modified carbon dot nanoparticles by

Author(s): Lester Thoo <sup>1</sup>, Mochamad Z Fahmi <sup>2</sup>, Ihsan N Zulkipli <sup>1</sup>, Natasha Keasberr

Affiliation(s): <sup>1</sup>PAPRSB Institute of Health Sciences, Universiti Brunei Darussalam, <sup>2</sup>Department

<sup>3</sup>Faculty of Science, Universiti Brunei Darussalam

Your submission has been received by the Molecules and Cells editorial office.

Please notify us ([home@ksmcb.or.kr](mailto:home@ksmcb.or.kr)) within 48 hours after submission if you have any inquiry or disapproval. Otherwise, your manuscript will enter the peer review process.

\*Similarity index of the MaC16-03-062: [15 %](#)

Similarity index (Crosscheck(tm) powered by iThenticate) is provided to inform the author to what extent the submitted manuscript overlaps with previously published articles. The index is provided to prevent possible plagiarism. Sincerely,

Rho Hyun Seong, Ph.D.

Editor-in-Chief

Molecules and Cells

URL: <http://www.molcells.org>